Detalhe da pesquisa
1.
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
Gynecol Oncol
; 169: 64-69, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36512912
2.
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
Gynecol Oncol
; 160(1): 71-76, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33139041
3.
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Cancer
; 126(6): 1274-1282, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31880826